Opinion|Videos|April 18, 2025
Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
Panelists discuss how effective communication about amyloid-targeting therapies requires transparent discussions of modest cognitive benefits alongside potential risks, particularly events related to amyloid-related imaging abnormalities (ARIA), while addressing practical considerations including treatment burden, infusion center logistics, monitoring requirements, costs, insurance coverage, and caregiver involvement to help patients and families make fully informed decisions aligned with their values and circumstances.
Advertisement
Video content above is prompted by the following:
- How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the infusion center, etc?
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
4
Preparing Practices for the Next Era of Hepatitis B Care
5